USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Growth Opportunities in the US Point-of-care Testing Market
Growth Opportunities in the US Point-of-care Testing Market
Digital Health Meets Point of Care—Emergence of Mobile Molecular Diagnostics
RELEASE DATE
23-Jun-2016
23-Jun-2016
REGION
North America
North America
Research Code: K081-01-00-00-00
SKU: LS00263-NA-MR_18682
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
LS00263-NA-MR_18682
Description
The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and market share analyses in each of these segments provide a thorough understanding of the competitive landscape. The analysis provides predictions on the future of the POCT market segments and key areas of investment that should be in the planning books for in vitro diagnostic device (IVD) companies operating in the POCT space.
RESEARCH: INFOGRAPHIC
This infographic presents a brief overview of the research, and highlights the key topics discussed in it.Click image to view it in full size
Table of Contents
Market Snapshot
Scope and Segmentation
Top Economic Motivators of Patient-centric POCT
Trends Driving POC Convergence
Trends/Factors Impacting the POCT Market
Future Trends—3 Big Predictions Driving POC Convergence
Market Definitions
POCT Tests Progression in the US
POCT Environment—Spectrum of Patient Care Testing
Market Drivers
Market Restraints
CLIA Waiver Provides Faster Access to US POCT MDx Segment with Ability to Gain more Penetration
Guide to Reimbursement—Tips from Payer Community on POCT
Retail Clinics
Global Retail Care Market Revenue—Realistic Scenario (2015–2022)
Notable Activities
Market Size and Growth Graph
Expected Penetration of POCTs
Macro to Micro Visioning
Growth Opportunities for Technology Providers
Future of POCT
Overcoming Barriers
Key Companies to Watch—Game Changers in Molecular POCT
Key Companies to Watch—Molecular Diagnostics POCT
Product Pipeline
Strategic Options for Startups in POCT
Top Predictions for the US POCT Market
The POCT Vendor Landscape
Point of Care Testing Landscape
Competitive Landscape for POCT Vendors by Test Type
Competitive Landscape for POCT Vendors by Test MethodologyCompetitor Segment Ranking Matrix
POCT Diagnostics Leaderboard
Forecast Assumptions
Revenue Forecast
Percent Revenue Forecast by Segment
Market Share Analysis
Revenue Forecast
Market Share Analysis
Product Spotlight
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Market Share Analysis
Alere
Enterix
Others
Partnering to Innovate—Beyond Conventional Boundaries
5 Competitive Keys for Success in POCT Space
Legal Disclaimer
Market Engineering Methodology
List of Abbreviations
List of Figures- 1. Overview of Healthcare Facilities, Serbia, 2015
- 2. Total POCT Market: Key Market Drivers, US, 2016–2020
- 3. Total POCT Market: Key Market Restraints, US, 2016–2020
List of Charts- 1. POCT Market: Percent Revenue Breakdown by Segment, US, 2016 and 2020
- 2. Retail Care Market: Revenue Forecast, Global, 2015–2022
- 3. POCT Market: Market Potential by Segment, US, 2015–2020
- 4. Total POCT Market: Revenue Forecast, US, 2012–2020
- 5. Total POCT Market: Percent Revenue Forecast by Segment, US, 2012–2020
- 6. Total POCT Market: Market Share Evolution, US, 2012 and 2015
- 7. Cardiac POCT Segment: Revenue Forecast, US, 2012–2020
- 8. Cardiac POCT Segment: Percent of Sales, US, 2015
- 9. Infectious Disease POCT Segment: Revenue Forecast, US, 2012–2020
- 10. Infectious Disease POCT Segment: Percent of Sales, US, 2015
- 11. Coagulation PT/INR POCT Segment: Revenue Forecast, US, 2012–2020
- 12. Coagulation PT/INR POCT Segment: Percent of Sales, US, 2015
- 13. Blood Gas & Electrolyte POCT Segment: Revenue Forecast, US, 2012–2020
- 14. Blood Gas & Electrolyte POCT Segment: Percent of Sales, US, 2015
- 15. Pregnancy POCT Segment: Revenue Forecast, US, 2012–2020
- 16. Pregnancy POCT Segment: Percent of Sales, US, 2015
- 17. Hematology POCT Segment: Revenue Forecast, US, 2012–2020
- 18. Hematology POCT Segment: Percent of Sales, US, 2015
- 19. HbA1c POCT Segment: Revenue Forecast, US, 2012–2020
- 20. HbA1c POCT Segment: Percent of Sales, US, 2015
- 21. Urinalysis POCT Segment: Revenue Forecast, US, 2012–2020
- 22. Urinalysis POCT Segment: Percent of Sales, US, 2015
- 23. Drugs of Abuse POCT Segment: Revenue Forecast, US, 2012–2020
- 24. Drugs of Abuse POCT Segment: Percent of Sales, US, 2015
- 25. Coagulation ACT/APTT POCT Segment: Revenue Forecast, US, 2012–2020
- 26. Coagulation ACT/APTT POCT Segment: Percent of Sales, US, 2015
- 27. Blood Glucose POCT Segment: Revenue Forecast, US, 2012–2020
- 28. Blood Glucose POCT Segment: Percent of Sales, US, 2015
- 29. Cholesterol POCT Segment: Revenue Forecast, US, 2012–2020
- 30. Cholesterol POCT Segment: Percent of Sales, US, 2015
- 31. FOBT/FIT POCT Segment: Revenue Forecast, US, 2012–2020
- 32. FOBT/FIT POCT Segment: Percent of Sales, US, 2015
Popular Topics
The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and market share analyses in each of these segments provide a thorough understanding of the competitive landscape. The analysis provides predictions on the future of the POCT market segments and key areas of investment that should be in the planning books for in vitro diagnostic device (IVD) companies operating in the POCT space.
| No Index | No |
|---|---|
| Podcast | No |
| Table of Contents | | Executive Summary~ || Market Snapshot~ || Scope and Segmentation~ || Top Economic Motivators of Patient-centric POCT~ || Trends Driving POC Convergence~ || Trends/Factors Impacting the POCT Market~ || Future Trends—3 Big Predictions Driving POC Convergence~ | Market Overview~ || Market Definitions~ || POCT Tests Progression in the US~ || POCT Environment—Spectrum of Patient Care Testing~ || Market Drivers~ || Market Restraints~ || CLIA Waiver Provides Faster Access to US POCT MDx Segment with Ability to Gain more Penetration~ || Guide to Reimbursement—Tips from Payer Community on POCT~ || Retail Clinics~ || Global Retail Care Market Revenue—Realistic Scenario (2015–2022)~ || Notable Activities~ || Market Size and Growth Graph~ || Expected Penetration of POCTs~ | Vision and Strategy—Growth Opportunities~ || Macro to Micro Visioning~ || Growth Opportunities for Technology Providers~ || Future of POCT~ || Overcoming Barriers~ || Key Companies to Watch—Game Changers in Molecular POCT~ ||| QuantuMDx~ ||| Ubiquitome~ ||| LucigenDx~ ||| GenePOC Diagnostics~ || Key Companies to Watch—Molecular Diagnostics POCT~ ||| Insilixa~ ||| Oxford Nanopore~ ||| DNA Electronics~ || Product Pipeline~ || Strategic Options for Startups in POCT~ || Top Predictions for the US POCT Market~ | Competitive Analysis~ || The POCT Vendor Landscape~ || Point of Care Testing Landscape~ || Competitive Landscape for POCT Vendors by Test Type~ || Competitive Landscape for POCT Vendors by Test MethodologyCompetitor Segment Ranking Matrix~ || POCT Diagnostics Leaderboard~ | Market Forecasts~ || Forecast Assumptions~ || Revenue Forecast~ || Percent Revenue Forecast by Segment~ || Market Share Analysis~ ||| Alere~ ||| Roche Diagnostics~ ||| Abbott Diagnostics~ ||| Siemens~ ||| Others~ | Cardiac POCT Segment~ || Revenue Forecast~ || Market Share Analysis~ ||| Alere~ ||| Roche~ ||| Siemens~ ||| Others~ || Product Spotlight~ | Infectious Disease POCT Segment~ || Market Share Analysis~ ||| Alere~ ||| Quidel~ ||| Meridien~ ||| Orasure~ ||| Others~ | Coagulation PT/INR POCT Segment~ || Market Share Analysis~ ||| Roche Diagnostics~ ||| Alere~ ||| Philips~ ||| Abbott Diagnostics~ ||| Others~ | Blood Gas & Electrolyte POCT Segment~ || Market Share Analysis~ ||| Abbott Laboratories~ ||| Radiometer~ ||| Siemens Healthcare Diagnostics~ ||| Instrumentation Laboratory~ ||| Roche~ ||| Others~ | Pregnancy POCT Segment~ || Market Share Analysis~ ||| Alere~ ||| Quidel~ ||| Beckman Coulter~ ||| Others~ | Hematology POCT Segment~ || Market Share Analysis~ ||| HemoCue~ ||| Abbott~ ||| Stanbio~ ||| Others~ | HbA1c POCT Segment~ || Market Share Analysis~ ||| Siemens~ ||| Alere~ ||| PTS Diagnostics~ ||| Others~ | Urinalysis POCT Segment~ || Market Share Analysis~ ||| Siemens~ ||| Roche~ ||| Arkray~ ||| Others~ | Drugs of Abuse POCT Segment~ || Market Share Analysis~ ||| Alere~ ||| Medtox~ ||| Others~ | Coagulation ACT/APTT POCT Segment~ || Market Share Analysis~ ||| Medtronic~ ||| Abbott~ ||| HelenaLaboratories~ ||| Accriva Diagnostics~ | Blood Glucose POCT Segment~ || Market Share Analysis~ ||| Roche~ ||| HemoCue~ ||| Nova Biomedical~ ||| Abbott~ ||| Others~ | Cholesterol POCT Segment~ || Market Share Analysis~ ||| Alere~ ||| PTS Diagnostics~ ||| Roche~ | FOBT/FIT POCT Segment~ || Market Share Analysis~ ||| Beckman Coulter~ || Alere~ || Enterix~ || Others~ | Conclusions~ || Partnering to Innovate—Beyond Conventional Boundaries~ || 5 Competitive Keys for Success in POCT Space~ || Legal Disclaimer~ | Appendix~ || Market Engineering Methodology~ || List of Abbreviations~ |
| List of Charts and Figures | 1. Overview of Healthcare Facilities, Serbia, 2015 ~ 2. Total POCT Market: Key Market Drivers, US, 2016–2020~ 3. Total POCT Market: Key Market Restraints, US, 2016–2020~| 1. POCT Market: Percent Revenue Breakdown by Segment, US, 2016 and 2020~ 2. Retail Care Market: Revenue Forecast, Global, 2015–2022~ 3. POCT Market: Market Potential by Segment, US, 2015–2020 ~ 4. Total POCT Market: Revenue Forecast, US, 2012–2020~ 5. Total POCT Market: Percent Revenue Forecast by Segment, US, 2012–2020~ 6. Total POCT Market: Market Share Evolution, US, 2012 and 2015~ 7. Cardiac POCT Segment: Revenue Forecast, US, 2012–2020~ 8. Cardiac POCT Segment: Percent of Sales, US, 2015~ 9. Infectious Disease POCT Segment: Revenue Forecast, US, 2012–2020~ 10. Infectious Disease POCT Segment: Percent of Sales, US, 2015~ 11. Coagulation PT/INR POCT Segment: Revenue Forecast, US, 2012–2020~ 12. Coagulation PT/INR POCT Segment: Percent of Sales, US, 2015~ 13. Blood Gas & Electrolyte POCT Segment: Revenue Forecast, US, 2012–2020~ 14. Blood Gas & Electrolyte POCT Segment: Percent of Sales, US, 2015~ 15. Pregnancy POCT Segment: Revenue Forecast, US, 2012–2020~ 16. Pregnancy POCT Segment: Percent of Sales, US, 2015~ 17. Hematology POCT Segment: Revenue Forecast, US, 2012–2020~ 18. Hematology POCT Segment: Percent of Sales, US, 2015~ 19. HbA1c POCT Segment: Revenue Forecast, US, 2012–2020~ 20. HbA1c POCT Segment: Percent of Sales, US, 2015~ 21. Urinalysis POCT Segment: Revenue Forecast, US, 2012–2020~ 22. Urinalysis POCT Segment: Percent of Sales, US, 2015~ 23. Drugs of Abuse POCT Segment: Revenue Forecast, US, 2012–2020~ 24. Drugs of Abuse POCT Segment: Percent of Sales, US, 2015~ 25. Coagulation ACT/APTT POCT Segment: Revenue Forecast, US, 2012–2020~ 26. Coagulation ACT/APTT POCT Segment: Percent of Sales, US, 2015~ 27. Blood Glucose POCT Segment: Revenue Forecast, US, 2012–2020~ 28. Blood Glucose POCT Segment: Percent of Sales, US, 2015~ 29. Cholesterol POCT Segment: Revenue Forecast, US, 2012–2020~ 30. Cholesterol POCT Segment: Percent of Sales, US, 2015~ 31. FOBT/FIT POCT Segment: Revenue Forecast, US, 2012–2020~ 32. FOBT/FIT POCT Segment: Percent of Sales, US, 2015~ |
| Author | Divyaa Ravishankar |
| WIP Number | K081-01-00-00-00 |
| Is Prebook | No |